Cochrane systematic review and meta-analysis of botulinum toxin for the prevention of migraine

2019135 citationsReviewgold Open Access

Authors

Clare P Herd · University of Birmingham

Claire L Tomlinson · University of Birmingham

Caroline Rick · University of Nottingham

William J. Scotton · University of Birmingham

Julie Edwards · Sandwell & West Birmingham Hospitals NHS Trust

Natalie Ives · University of Birmingham

Carl E Clarke

Abstract

In chronic migraine, botulinum toxin reduces migraine frequency by 2 days/month and has a favourable safety profile. Inclusion of medication overuse headache does not preclude its effectiveness. Evidence to support or refute efficacy in episodic migraine was not identified.

Topics & Keywords

Migraine and Headache Studies Botulinum Toxin and Related Neurological Disorders Sympathectomy and Hyperhidrosis Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: BMJ Open

Volume 9, Issue 7, pp. e027953-e027953

DOI: 10.1136/bmjopen-2018-027953

Field-Weighted Citation Impact: 9.86